Want to see JP:4579 full AI Analyst Report?
4579 Stock Chart & Stats
¥1010.00
-¥6.00(-1.49%)
At close: 4:00 PM EST
¥1010.00
-¥6.00(-1.49%)
Day’s Range― - ―
52-Week Range¥438.00 - ¥1,465.00
Previous CloseN/A
Volume117.60K
Average Volume (3M)141.95K
Market Cap
¥15.46B
Enterprise Value¥10.30K
Total Cash (Recent Filing)¥4.70B
Total Debt (Recent Filing)¥2.69B
Price to Earnings (P/E)66.4
Beta1.00
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.95
Shares Outstanding26,031,412
10 Day Avg. Volume113,870
30 Day Avg. Volume141,950
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.47
Price to Sales (P/S)6.01
P/FCF Ratio-56.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)48.4
Revenue Forecast (FY)¥4.59B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRapid year-over-year revenue growth indicates improving commercial or collaboration activity and provides a stronger base for future milestone and royalty opportunities. If sustained, this expansion can improve operating leverage and support reinvestment in the company’s drug-development pipeline.
Strong Gross MarginsThe very high gross margin and positive operating margin show that recent revenue is converting into operating profit with limited direct cost burden. This supports the economics of an asset-light partnering model, although continued pipeline progress is needed to sustain earnings.
Solid Balance SheetEquity funds most assets and leverage is moderate, giving RaQualia a relatively resilient financial base for ongoing research and development. This balance-sheet capacity can reduce dependence on external financing while the company advances candidates through clinical development.
Bears Say
Volatile ProfitabilityThe return to profit is encouraging, but the history of losses and earnings below earlier peak levels shows that profitability is not yet consistently established. Such volatility can make internal funding and long-term planning more dependent on licensing outcomes.
Inconsistent Cash GenerationPositive TTM operating and free cash flow represent improvement, yet the multi-year pattern remains uneven and cash generation is modest relative to revenue. Repeated swings between positive and negative cash flow could constrain the company’s ability to fund development without financing or partner proceeds.
Low Returns And Rising DebtLow return on equity indicates that the enlarged equity base is not yet producing strong shareholder returns. Although leverage remains manageable, debt growth adds future repayment and interest obligations, reducing flexibility if drug-development milestones or licensing income are delayed.
RaQualia Pharma Inc. News
4579 FAQ
What was RaQualia Pharma Inc.’s price range in the past 12 months?
RaQualia Pharma Inc. lowest stock price was ¥438.00 and its highest was ¥1465.00 in the past 12 months.
What is RaQualia Pharma Inc.’s market cap?
RaQualia Pharma Inc.’s market cap is ¥15.46B.
When is RaQualia Pharma Inc.’s upcoming earnings report date?
RaQualia Pharma Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 45 days.
How were RaQualia Pharma Inc.’s earnings last quarter?
RaQualia Pharma Inc. released its earnings results on Aug 14, 2026. The company reported -¥9.26 earnings per share for the quarter.
Is RaQualia Pharma Inc. overvalued?
According to Wall Street analysts RaQualia Pharma Inc.’s price is currently Overvalued.
Does RaQualia Pharma Inc. pay dividends?
RaQualia Pharma Inc. does not currently pay dividends.
What is RaQualia Pharma Inc.’s EPS estimate?
RaQualia Pharma Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RaQualia Pharma Inc. have?
RaQualia Pharma Inc. has 26,031,412 shares outstanding.
What happened to RaQualia Pharma Inc.’s price movement after its last earnings report?
RaQualia Pharma Inc. reported an EPS of -¥9.26 in its last earnings report. Following the earnings report the stock price went down -0.775%.
Which hedge fund is a major shareholder of RaQualia Pharma Inc.?
Currently, no hedge funds are holding shares in JP:4579
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaQualia Pharma Inc.
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.